Radiomics Market Primer

Our downloadable Radiomics Market Primer explores the emerging role of radiomics in disease characterization, outcomes prediction, and therapy selection—highlighting key players, regulatory progress, and the field’s untapped potential for transformative clinical impact.

 

Table of Contents

  • Defining Radiomics
  • Number of PubMed Articles Mentioning “Radiomic” (2015 –2025)
  • Overview of Radiomic Applications
  • Select Radiomics Companies by Application
  • Select Radiomics Companies by Therapeutic Area
  • Top 20 Pharma Activity –PubMed Publication Analysis
  • Clinical Trials Analysis

 

Informed by KOL interviews and publicly available information including publications, clinical trials, and company materials

Complete this form to receive a free copy

 

Key Takeaways:

  • Radiomics is typically characterized by quantitative feature extraction and analysis from medical imaging
  • Radiomics applications span disease detection / quantification, complex disease characterization, and outcomes prediction
  • Unsurprisingly, commercial activity is greatest in automation and quantification of medical imaging features and identification of irregularities; many of these companies have received FDA clearance or CE-IVD approval, with some early clinical adoption
  • Numerous pharma and radiomics companies are exploring precision medicine-based approaches, linking radiomics algorithms to disease prognosis and treatment response
  • Pharma companies like Bayer, Roche / Genentech, Novartis, BMS, Merck, and Gilead have published data exploring radiomics for therapy response prediction
  • There has been a steady increase in radiomic publications over the last 10 years, however we have yet to see a steep “hockey stick” increase, suggesting that we still await “killer applications” with demonstrated clinical benefit

About the Contributors:

63fd481940d99e8cc3c49598_6112bcecdffd6150b1a6b077_60bf2d6e8a2a979828898bcc_Tina-circle-headshot-p-500
Tina Wang
Senior Project Leader

Tina leads engagements centered around market opportunity assessments, commercialization strategy, and VOC feedback. Her experience spans diagnostics, research tools, and novel techs, with a strong focus in precision oncology diagnostics (e.g., liquid biopsy, digital pathology, radiomics). Tina leads DeciBio’s radiomics practice area.

Connect on LinkedIn
63fd4812b41ee74f1563ba9c_614e5e6a8e0674c481ee1f9c_4S3A2601-Edit-crop-p-500

Hannah Glazier

Product Manager
Pharma | Diagnostics | Commercial
63fd4812df1823c9125303ae_635097f03fcc55f5eee8307b_Graham circleheadshot-p-500

Graham Friedman

Associate

Research Tools | Oncology Biomarkers

66bb3057de3d027560d48803_Arnav Jolly_20240813-p-500

Arnav Jolly

Senior Analyst

Diagnostics | Research Tools

©2025 DeciBio. All rights reserved.